Ignite Creation Date:
2024-05-06 @ 3:44 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04749485
Status:
UNKNOWN
Last Update Posted:
2021-02-11
First Post:
2021-02-07
Brief Title:
A Study of HX008 for the Treatment of Patients With Malignant Melanoma
Sponsor:
Taizhou Hanzhong biomedical co LTD
Organization:
Taizhou Hanzhong biomedical co LTD
Study Overview
Official Title:
A Single-armed Open-labeled Phase II Study of HX008 a Humanized Monoclonal Antibody Targeting PD-1 for the Treatment of Patients With Locally Advanced or Metastatic Melanoma Who Have Failed the Standard Treatments
Status:
UNKNOWN
Status Verified Date:
2021-02
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface restores T cell activity thus enhancing immune response and has potential to treat various types of tumors In this study the efficacy and safety of HX008 in patients with locally advanced or metastatic melanoma who have failed the standard treatments will be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None